LOW DOSE INHALED NITRIC OXIDE FOR TREATMENT AND PREVENTION

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objective of this project, which is part of a multicenter trial, is to investigate whether low dose inhaled nitric oxide (iNO) will decrease the risk of chronic lung disease in premature infants. The intervention is expected to increase survival without chronic lung disease (oxygen dependence at 36 weeks post-menstrual age) from 50 to 62 percent. Infants are eligible if they are less than 32 weeks gestational age, 500 to 1250 g birth weight, 7 to 21 days old, and require mechanical ventilation. Subjects are randomly assigned to receive iNO (initial dose 20 ppm) or placebo. The study gas is weaned over a three week period. Safety is evaluated by monitoring clinical bleeding and intracranial hemorrhage, complications of prematurity, and neurodevelopmental outcome at two years of age.